cache/5185edea8b2cf1f879170fb0afb60aa457720fdfa1a2d5bcfbab5154c4a13a23

COM:KURMAPARTNERS

Minoryx

  • Privately Held

Minoryx is a biotechnology company focused on the discovery and development of novel therapies for orphan diseases. The company's lead product candidate is leriglitazone (MIN-102), an orally bioavailable, brain-penetrant, small molecule that has been granted orphan drug status for the treatment of X-linked adrenoleukodystrophy (X-ALD).

peer of

invested in

investor of